Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Management of Metastatic Bone Disease and Hypercalcemia of Malignancy
Allan Lipton
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
16
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Management of Metastatic Bone Disease and Hypercalcemia of Malignancy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bisphosphonates
100%
Metastatic Bone Disease
100%
Hypercalcemia of Malignancy
100%
Bone Metastasis
50%
Zoledronic Acid
40%
Multiple Myeloma
30%
Breast Cancer
20%
Osteoclast
20%
Intravenous Bisphosphonates
20%
Malignant Bone Disease
20%
Clinical Evidence
10%
Solid Tumors
10%
In Cancer
10%
Bone Destruction
10%
Cancer Patients
10%
Lung Cancer
10%
Nitrogen Compounds
10%
Skeletal Complications
10%
Bone Resorption
10%
Intravenous Infusion
10%
Chemical Engineering
10%
Serum Calcium
10%
Antitumor Activity
10%
Patients with Breast Cancer
10%
American Society of Clinical Oncology
10%
Bone Health
10%
Bone Pain
10%
Prostate Cancer Patients
10%
Antineoplastic Agents
10%
Apoptosis Induction
10%
Clodronate
10%
Cancer Treatment-induced Bone Loss
10%
Mevalonate Pathway
10%
Early Breast Cancer
10%
Metabolic Effects
10%
Tumor Bone
10%
Osteolytic Metastasis
10%
Renal Safety
10%
New Nitrogen
10%
Osteolytic
10%
Ibandronate
10%
Protein Prenylation
10%
Osteoclast Activation
10%
Skeletal Tumor Burden
10%
Lower Molar
10%
Osteolytic Bone Lesions
10%
Nitrogen-containing Bisphosphonates
10%
Pharmacology, Toxicology and Pharmaceutical Science
Bisphosphonic Acid Derivative
100%
Hypercalcaemia
100%
Bone Disease
100%
Bone Metastasis
46%
Breast Cancer
30%
Zoledronic Acid
30%
Multiple Myeloma
23%
Pamidronic Acid
23%
Malignant Neoplasm
15%
Nitrogen
15%
Solid Malignant Neoplasm
7%
Bone Destruction
7%
Bone Tumor
7%
Bone Cancer
7%
Prostate Cancer
7%
Preclinical Study
7%
Bone Lesion
7%
Lung Cancer
7%
Anticarcinogen
7%
Antitumor Activity
7%
Bone Pain
7%
Clodronic Acid
7%
Mevalonic Acid
7%